Results 1 to 10 of about 60,513 (321)
The Journal of Clinical Investigation, 2022 Myeloproliferative neoplasms (MPNs) are associated with significant alterations in the bone marrow microenvironment that include decreased expression of key niche factors and myelofibrosis. Here, we explored the contribution of TGF-β to these alterations
Juo-Chin Yao +8 more
doaj +2 more sources
Blood Advances, 2020 Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in 2005, fedratinib was developed as a small molecular inhibitor of JAK2. It was optimized to yield low-nanomolar activity against JAK2 (50% inhibitory concentration = 3 nM)
A. Mullally +3 more
semanticscholar +4 more sources
The odyssey of pacritinib in myelofibrosis
Blood Advances, 2022 Visual ...
S. Venugopal, J. Mascarenhas
semanticscholar +3 more sources
Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials [PDF]
eJHaemIntroduction Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life.
Ruben A. Mesa +11 more
doaj +2 more sources
Successful Management of Lupus‐Associated Autoimmune Myelofibrosis with Tofacitinib: A Case Report [PDF]
ACR Open RheumatologyWe report a case of a 34‐year‐old woman with systemic lupus erythematosus (SLE) who developed thrombocytopenia and was diagnosed with lupus‐associated autoimmune myelofibrosis.
Hamidreza Soltani, Ali Dehghan
doaj +2 more sources
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
American journal of hematology/oncology, 2023 Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin ...
A. Tefferi
semanticscholar +1 more source
Journal of Clinical Oncology, 2023 PURPOSE Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need.
J. Mascarenhas +23 more
semanticscholar +1 more source
Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity
Frontiers in Pediatrics, 2022 Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this ...
Fabiola Guerra +12 more
doaj +1 more source
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
Cancer, 2023 Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype.
F. Palandri +39 more
semanticscholar +1 more source